PIMCO New York Municipal Income Fund III (PYN) Forms $8.72 Double Bottom; Agios Pharmaceuticals, Inc. (AGIO) Had 12 Bullish Analysts

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Logo

PIMCO New York Municipal Income Fund III (PYN) formed double bottom with $8.28 target or 5.00% below today’s $8.72 share price. PIMCO New York Municipal Income Fund III (PYN) has $49.72M valuation. The stock increased 0.80% or $0.069 during the last trading session, reaching $8.719. About 1,067 shares traded. PIMCO New York Municipal Income Fund III (NYSE:PYN) has declined 8.99% since May 4, 2017 and is downtrending. It has underperformed by 20.54% the S&P500.

Among 16 analysts covering Agios Pharmaceuticals (NASDAQ:AGIO), 12 have Buy rating, 0 Sell and 4 Hold. Therefore 75% are positive. Agios Pharmaceuticals had 45 analyst reports since July 23, 2015 according to SRatingsIntel. On Wednesday, August 5 the stock rating was maintained by Roth Capital with “Hold”. Credit Suisse maintained the shares of AGIO in report on Wednesday, April 11 with “Outperform” rating. As per Thursday, June 1, the company rating was maintained by Oppenheimer. The stock of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) has “Outperform” rating given on Wednesday, August 2 by Leerink Swann. Cowen & Co maintained the shares of AGIO in report on Tuesday, August 8 with “Buy” rating. The company was upgraded on Monday, June 13 by JP Morgan. The stock of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) earned “Buy” rating by Needham on Friday, September 15. On Wednesday, February 14 the stock rating was maintained by RBC Capital Markets with “Buy”. As per Monday, June 26, the company rating was maintained by Oppenheimer. The stock of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) earned “Outperform” rating by Credit Suisse on Wednesday, May 18. See Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) latest ratings:

11/04/2018 Broker: Credit Suisse Old Rating: Outperform New Rating: Outperform Old Target: $80 New Target: $95 Maintain
15/02/2018 Broker: JP Morgan Old Rating: Overweight New Rating: Overweight Old Target: $76 New Target: $85 Maintain
15/02/2018 Broker: Credit Suisse Rating: Buy New Target: $80.0 Maintain
14/02/2018 Broker: RBC Capital Markets Rating: Buy New Target: $88.0 Maintain
19/11/2017 Broker: SunTrust Rating: Buy New Target: $80.0 Maintain

More recent Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) news were published by: Benzinga.com which released: “The Week Ahead In Biotech: PDUFA Dates, Clinical Trials, Merck And Pfizer Earnings On Tap” on April 29, 2018. Also Nasdaq.com published the news titled: “Agios Announces Revised Starting Time of 8:00am ET for Investor Day and First Quarter 2018 Financial Results …” on April 27, 2018. Streetinsider.com‘s news article titled: “Agios Pharma (AGIO), Jounce Therapeutics (JNCE) Gain on Celgene (CELG) Speculation” with publication date: April 09, 2018 was also an interesting one.

Investors sentiment increased to 1.22 in 2017 Q4. Its up 0.01, from 1.21 in 2017Q3. It improved, as 19 investors sold Agios Pharmaceuticals, Inc. shares while 48 reduced holdings. 27 funds opened positions while 55 raised stakes. 45.70 million shares or 2.27% more from 44.69 million shares in 2017Q3 were reported. Schwab Charles Inv has 121,975 shares. Valley Advisers has 0% invested in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO). Pdts Prtn Lc invested in 0.25% or 151,268 shares. Whittier Tru Of Nevada holds 0% or 140 shares in its portfolio. Tower Rech Capital Lc (Trc) invested in 0% or 68 shares. Ubs Asset Americas Inc has 0.02% invested in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) for 345,284 shares. Bnp Paribas Asset Hldg stated it has 0.12% in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO). Capital International Ca invested in 0.35% or 32,190 shares. Oppenheimer & Company accumulated 20,099 shares or 0.03% of the stock. Fernwood Invest Limited Liability Co has 27,550 shares for 0.84% of their portfolio. Metropolitan Life Ins holds 0% of its portfolio in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) for 2,957 shares. Alkeon Capital Ltd owns 511,619 shares. Public Employees Retirement Association Of Colorado holds 0% or 6,769 shares. Credit Suisse Ag, a Switzerland-based fund reported 33,978 shares. Gam Hldgs Ag invested in 0.04% or 24,200 shares.

The stock increased 0.29% or $0.24 during the last trading session, reaching $82.66. About 85,802 shares traded. Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) has risen 41.40% since May 4, 2017 and is uptrending. It has outperformed by 29.85% the S&P500.

Since January 10, 2018, it had 1 buy, and 21 insider sales for $17.22 million activity. 13,000 shares were sold by Schenkein David P, worth $1.01M. Biller Scott sold $249,229 worth of stock or 3,000 shares. Bowden Christopher also sold $155,305 worth of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) shares. On Friday, January 12 Alenson Carman sold $161,250 worth of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) or 2,150 shares. Hoerter Steven L. sold $1.87M worth of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) on Tuesday, January 23. On Monday, March 19 Foster-Cheek Kaye I sold $557,396 worth of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) or 6,800 shares. Another trade for 200 shares valued at $16,688 was made by Scadden David on Friday, March 16.

Agios Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of medicines for the treatment of cancer and rare genetic metabolic disorders in the United States. The company has market cap of $4.76 billion. It is developing Enasidenib, a potent inhibitor of the mutated isocitrate dehydrogenase 2 protein that is in Phase 1/2 clinical trial for patients with advanced hematologic malignancies with an IDH 2 mutation; Phase 3 clinical trial for patients with IDH2 mutant-positive acute myeloid leukemia (AML); Phase 1b frontline combination trial for patients with newly diagnosed AML with an IDH2 or IDH1 mutation; and Phase 1/2 frontline combination trial for patients with newly diagnosed AML. It currently has negative earnings. The firm is also developing Ivosidenib, a potent inhibitor of the mutated IDH1 protein, which is in Phase 1 clinical trial for patients with advanced hematologic malignancies with an IDH1 mutation; Phase 1 clinical trial for advanced solid tumors; Phase 3 clinical trial for patients with nonresectable or metastatic cholangiocarcinoma with an IDH1 mutation; Phase 1b frontline combination trial for patients with newly diagnosed AML with an IDH2 or IDH1 mutation; and Phase 1/2 frontline combination and Phase 3 clinical trials for newly diagnosed AML patients.

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Ratings Chart